IL13 and cancer: TSA treatment enhanced the cytotoxicity of IL-13-PE in IL-13Rα2-negative cancer cells (IC50 40-50 ng/ml with 5 μM TSA), but not in normal cells (IC50 > 1000 ng/ml with 5 μM TSA).